Multiple Analysts Lower Iovance Biotherapeutics Price Targets Amid Weak Earnings

Multiple analysts have recently lowered their price targets for Iovance Biotherapeutics (IOVA) despite maintaining mostly positive ratings. Mizuho Securities significantly reduced its price target from $30.00 to $10.00 while reaffirming an "Outperform" rating. Barclays also cut its target from $5.00 to $4.00 but kept an "Overweight" rating, indicating a positive outlook. HC Wainwright decreased its target to $20.00 with a buy rating, while Chardan Capital lowered theirs to $25.00, also maintaining a buy rating. The company reported a quarterly loss that missed earnings estimates and revenue below expectations, contributing to the cautious adjustments. Overall, the consensus rating remains a "Moderate Buy" with an average price target around $16.33, reflecting tempered optimism amid financial challenges.